Clinical Trial Update: Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the PET/MRI tracer [18F] FAPI-74 for imaging in patients with refractory dermatomyositis; the study is currently NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• [18F] FAPI-74 (Fluorine-18 labeled fibroblast activation protein inhibitor FAPI-74)

Snippet

Sponsor: Farshad Moradi | Conditions: Refractory Dermatomyostitis | Phase 2 | Status: NOT_YET_RECRUITING